ZEVRA THERAPEUTICS, INC. · Drugmakers

ZVRA

Moderate riskNext report: In 7 days (est.)

View price ↗

The short version

A profitable company with growing sales. Institutions are adding.

Going well

Sales up 53% in the latest quarter vs a year ago
Profitable, keeps 78% of sales as profit
Sales up 351% last year

Money moves

Insiders sold $225K in the last 30 days, all through pre-planned sales
Institutions added 11% to their holdings in the quarter ending June 2026 (93 bought, 57 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$9.51-2.9% that day

Company value: $565M; Share price times all shares
Price vs profit (P/E): 10.3x; You pay about $10 for each $1 of yearly profit
Price vs sales: 4.2x; Company value is 4.2 times a year of sales
Cash vs value: 26%; Cash as a share of company value
Debt vs value: 11%; Debt as a share of company value

From ZVRA's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$39.7M+53% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $136.1M, up 119% from the 12 months before. Over 5 years, sales grew about 52% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of ZVRA. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +52% a yearProfit margin43%Last 12 months: 42.8%P/E at the end10xToday: 10.3x. Many steady companies trade at 12x to 25xShare count change0% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$505M

Profit in 5 years$217M

Price these guesses point to$36.58+285% vs $9.51 todayAbout +31% a year, before dividends

What today's price needs: with a 43% margin and a 10x P/E, sales could shrink about 0.7% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

3/5Mixed

PassReturn on equity 15%+Earns a lot on the money owners have in the business.85.7%
PassDebt under half of equityNot relying on borrowed money.0.40x equity
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.78.2%
MissProfitable every yearSteady profits, not one good year.1 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$2.4M

Revenue: $106.5M; +350.9% vs prior year
5-year growth: +51.6%/yr; revenue, per year
Total debt: $61.9M; 0.40x equity
Current ratio: 5.68x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 5

Revenue: $39.7M; +53.3% YoY
EPS: $0.14; vs $1.21
Op. margin: 42.3%; +316.8 pts
Free cash flow: $16.8M
Share count: +8.9%; vs a year ago

Insider rating

Last 90 days

47Mixed

Pre-planned sales of $225K (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.8
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+11.2%

Institutions added 11.2% to their holdings. 93 bought, 57 sold. 2 quarters of net buying in a row.

Shares held by institutions46.6M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+20.7%

Cash runwayAt last year's cash burn

1091 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

59M

Why moderate risk

Share count growing 20.7% a year (dilution)

Earnings reports

Last 12

Next reportIn 7 days (est.)Estimated from the same quarter last year

Results filedAug 5
Results filedMay 6
Results filedMar 9
Results filedNov 5, 2025
Results filedAug 12, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (passive)Aug 14 · View filing ↗Big holder 5%+ holder update (passive)Aug 6 · View filing ↗Big holder New 5%+ holder (passive)Jul 31 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$225K1 insider, 1 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Neil F. McfarlanePresident and CEO	Sell	20K	$11.25	$225K	417K	Oct 12Filing ↗
-4.6% of their holdings Pre-planned sale (10b5-1) Also Director Filed 1 day after